Cite
HARVARD Citation
Reisinger, E. et al. (2018). Immunogenicity, safety, and tolerability of the measles-vectored chikungunya virus vaccine MV-CHIK: a double-blind, randomised, placebo-controlled and active-controlled phase 2 trial. Lancet. 392 (10165), pp. 2718-2727. [Online].